OTC 抗体 (AA 51-150)
-
- 抗原 See all OTC 抗体
- OTC (Ornithine Carbamoyltransferase (OTC))
-
抗原表位
- AA 51-150
-
适用
- 人
-
宿主
- 兔
-
克隆类型
- 多克隆
-
标记
- This OTC antibody is un-conjugated
-
应用范围
- Western Blotting (WB), ELISA
- 交叉反应
- 人
- 预测反应
- Mouse,Rat,Dog,Cow,Pig,Horse
- 纯化方法
- Purified by Protein A.
- 免疫原
- KLH conjugated synthetic peptide derived from human OTC
- 亚型
- IgG
- Top Product
- Discover our top product OTC Primary Antibody
-
-
- 应用备注
-
WB 1:300-5000
ELISA 1:500-1000 - 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- 1 μg/μL
- 缓冲液
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
- 储存液
- ProClin
- 注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- 储存条件
- 4 °C,-20 °C
- 储存方法
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
- 有效期
- 12 months
-
- 抗原
- OTC (Ornithine Carbamoyltransferase (OTC))
- 别名
- OTC (OTC 产品)
- 别名
- OCTD antibody, 2810428A13Rik antibody, AA589422 antibody, AW457381 antibody, OCT antibody, Plxn2 antibody, mKIAA0463 antibody, F1B16.13 antibody, F1B16_13 antibody, ORNITHINE CARBAMOYLTRANSFERASE antibody, ornithine carbamoyltransferase antibody, BA4351 antibody, PSPTO4164 antibody, PLXN2 antibody, AI265390 antibody, Sf antibody, spf antibody, si:dkey-19h21.3 antibody, ornithine carbamoyltransferase antibody, plexin A2 antibody, ornithine carbamoyltransferase ArgF antibody, ornithine transcarbamylase antibody, OTC antibody, Plxna2 antibody, Otc antibody, argF antibody, argF-2 antibody, atpD-2 antibody, CNC04300 antibody, PLXNA2 antibody, otc antibody
- 背景
-
Synonyms: OCTD, Ornithine carbamoyltransferase, mitochondrial, Ornithine transcarbamylase, OTCase, OTC
Background: Defects in OTC are the cause of ornithine carbamoyltransferase deficiency (OTCD) [MIM:311250]. OTCD is an X-linked disorder of the urea cycle which causes a form of hyperammonemia. Mutations with no residual enzyme activity are always expressed in hemizygote males by a very severe neonatal hyperammonemic coma that generally proves to be fatal. Heterozygous females are either asymptomatic or express orotic aciduria spontaneously or after protein intake. The disorder is treatable with supplemental dietary arginine and low protein diet. The arbitrary classification of patients into the 'neonatal' group (clinical hyperammonemia in the first few days of life) and 'late' onset (clinical presentation after the neonatal period) has been used to differentiate severe from mild forms.
- 基因ID
- 5009
- UniProt
- P00480
-